Element Biosciences launched their AVITI sequencing platform (link to spec sheet) today and Illumina now have two new competitors in almost as many months (read my post on Singular from January). The Element pitch is to offer the highest data quality, lowest cost, and best […]
The new G4 benchtop sequencer from Singular Genomics is here. Sept 17th 2021 saw the first picture of the G4 in the wild from Beth Israel Deaconess Medical Center (see below). For anyone still recovering from a 2021 New Year’s hangover, the G4 is a […]
I thought I’d share my roundup of recent reviews that highlight the opportunities, challenges and current state-of-the-art in MRD analysis for solid tumours…enjoy! Moding 2021 (Cancer Discov.): Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease a review from Ash Alizadeh and Max […]
The news (thanks @danravicher) from the recent Illumina vs BGI_MGI that the invalidity of the ‘444 patent means BGI_MGI can enter the US market in 2022 was very interesting. Does it mean Illumina are worrying about new competition – I am not so sure. The […]
I missed the announcement last Summer on Christian Henry’s move to PacBio as their new President & CEO, taking over from Mike Hunkapiller who recently retired – these are some big boots to fill! Christian was was previously Illumina EVP and CFO, having held the CFO […]
Many of my followers in the cancer space, especially the Hemes folks, will already understand what MRD is and why it’s important. But for those of you who don’t know I thought an explainer might be helpful. I took inspiration from Keiths COVID qPCR explainer and this […]
A recent paper in The Lancet Microbe reports the first data from CovidNudge: DnaNudge’s rapid, lab-free COVID-19 test. The test: DnaNudge uses a SNP-genotyping technology developed by The Technology Partnership in Cambridge and explained in US10093965B2 patent. A sample is introduced into the Nudge cartridge, a disposable, sealed, and integrated lab-on-chip device, […]
Wow Illumina just spent $8 billion buying GRAIL; arguably the leader in methylation-based early detection of cancer with their Galleri test (read the press release). Get more info over at the website they’ve put together for the deal at transformingcancerdetection.com, which includes a presentation that also highlights […]
CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below). The method was […]
The UK biotech sector was in the news yesterday morning with two companies and their COVID tests making headlines: Oxford Nanopore and DNANudge. Both are offering rapid testing for COVID-19 in the NHS and in care homes (where they are desperately needed). There is only […]
